跳至主要内容
临床试验/NCT06625801
NCT06625801尚未招募不适用

Intravascular Ultrasound Guidance for Complex High-risk Indicated Procedures in Underrepresented Patient Populations Registry

ECRI bv0 个研究点目标入组 1,010 人开始时间: 2025年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,010
主要终点
Target-vessel failure (TVF)

研究概览

简要总结

The IVUS CHIP UPP Registry is a prospective, observational, multicenter, single-arm registry. A total of 1010 patients with complex coronary lesions will be enrolled in up to 2 years, with at least 500 men and women. All patients will be treated with IVUS-guided PCI.

详细描述

Objective is to describe in a United States population the clinical efficacy and safety of an IVUS-guided approach in patients who self-identify within a census-defined minority undergoing PCI of complex coronary lesions, as well as clinical outcomes up to 2 years.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient must be ≥18 years of age and self-identify within a US census-defined minority
  • Patients with an indication for PCI of at least one lesion satisfying any of the following criteria:
  • Angiographic heavy calcification
  • Ostial lesions
  • True bifurcation lesions involving side-branches >2.5mm
  • Left main lesions
  • Chronic total occlusion
  • In-stent restenosis
  • Long-lesions (estimated stent length > 28mm) OR Patient with an indication for PCI for any lesion and in need for elective mechanical circulatory support assisted PCI
  • Presenting with silent ischemia, stable angina, unstable angina or non-ST-elevation acute coronary syndrome (NSTE-ACS)
  • All lesions must be suitable for treatment with FDA-approved contemporary generation drug eluting stents or drug-coated balloons
  • The patient is willing and able to cooperate with registry procedures and follow-up until registry completion
  • Subject is able to confirm understanding of risks, benefits and treatment alternatives and he/she (or an authorized legal representative) provides informed consent prior to any protocol-related procedure, as approved by the appropriate IRB

排除标准

  • ST-elevation myocardial infarction or cardiogenic shock within prior 7 days
  • Known untreated severe valvular heart disease
  • Contraindication on the use of IVUS (i.e. extreme vessel tortuosity)
  • Requiring PCI in a diseased aorto-coronary bypass
  • Known contraindication or hypersensitivity to anticoagulants
  • Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to antiplatelet drugs, including both aspirin and P2Y12 inhibitors
  • Non-cardiac co-morbidities with a life expectancy less than 1 year
  • A patients that is currently participating in a clinical trial that has not yet reached its primary endpoint cannot be included in this registry. A patient may only be enrolled in this registry once.

结局指标

主要结局

Target-vessel failure (TVF)

时间窗: 1 year after enrollment

TVF is defined as a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target-vessel revascularization

次要结局

未报告次要终点

研究者

发起方
ECRI bv
申办方类型
Industry
责任方
Sponsor

相似试验